Completed PHASE2 INTERVENTIONAL NCT00037596

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Acute Myeloid Leukemia

Interventions Gemtuzumab Ozogamicin cytarabine.

Updated 5 times since 2017 Last updated: Feb 11, 2013 Started: Aug 31, 2000 Primary completion: Apr 30, 2003 Completion: Apr 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Myeloid Leukemia and is currently completed. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.